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supportive care after randomization and same D regimen after ﬁrst evi-
dence of PD). Primary endpoint was overall survival (OS). Additional 
analyses included tumor response, toxicity, progression-free survival 
(PFS) and quality of life (QoL). 
Results: Table below summarizes results through May 6, 2007. Final 
data will be available in July. Enrollment totaled 564 patients; 393 pa-
tients received 4 cycles of GC therapy, and 308 patients were random-
ized equally to immediate D and delayed D groups. Patient demograph-
ics were well balanced between D arms. Initial GC therapy was well 
tolerated with major toxicities represented in myelosuppression, but 
only 7.7% of patients experienced G4 thrombocytopenia. D delivered 
immediately following GC therapy had a manageable toxicity proﬁle 
comparable to the delayed D arm. Post-randomization, a notable num-
ber of patients in the delayed D arm (N=60) never received D therapy, 
mainly due to PD or personal decision to discontinue. PFS in the im-
mediate D arm (6.0 months) was signiﬁcantly greater (p=<0.0001) than 
in the delayed D arm (2.8 months). OS trended in favor of immediate 
D therapy (11.9 months) by 2.5 months compared to delayed D therapy 
(9.4 months), but was not statistically signiﬁcant (p=0.1065). QoL 
average symptom burden index based on responses to a Lung Cancer 
Symptom Scale survey was not statistically different (p=0.43) compar-
ing the two D arms. 
Conclusions: NSCLC patients can be administered D immediately 
after ﬁrst-line GC therapy without a sacriﬁce in either toxicity or QoL. 
While the PFS analysis for each D group suggests a possible clinical 
beneﬁt for immediate D therapy, the OS result trended in favor of im-
mediate D therapy, but did not reach statistical signiﬁcance. 
Characteristic/Result Initial GC Delayed D Immediate D
N enrolled/randomized 564 155 153
 Mean age (range) 65 (36-87) 65 (36-85) 65 (41-87)
 Performance status 0,1:2, % 89:11 89:11 93:7
 Stage IIIB:IV, % 14:85 16:83 18:82
N assessed for safety 560 95 145
 G3-4 Neutropenia, % 31.8 33.7 33.1
 G3/G4 Thrombocytopenia, % 20.4/7.7 0/0 1.4/0
 G3-4 Febrile neutropenia, % 1.8 1.1 3.5
 G3-4 Anemia, % 13.0 0 0.7
 G3-4 Fatigue, % 5.9 3.2 9.6
 G3-4 Vomiting, % 2.3 1.1 0
 G3-4 Diarrhea, % 0.4 5.3 0.7
 G3-4 Neuropathy, % 0 0 0
 G3-4 Myalgia, % 0.2 1.1 0.7
 G3-4 Asthenia, % 2.1 1.1 2.1
N assessed for response 393 95 145
 Overall response rate (CR+PR), % 38.9 9.5 11.7
N assessed for survival - 155 153
 Median OS, months - 9.4 11.9
 12 Month survival rate, % - 41.2 48.3
 Patients censored for OS, n (%) - 25 (16.1%) 34 (22.2%)
 Median PFS, months - 2.8 6.0
 Patients censored for PFS, n (%) - 10 (6.4%) 9 (5.9%)
P2-306 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Epoetin beta (EPO) together with Carboplatin/Gemcitabine 
(CaGem) chemotherapy for advanced NSCLC: A phase II study 
with matched controls
Schytte, Tine; Hansen, Olfred; Sørensen, Peter; Hansen, Karin H.; 
Odense University Hospital, Odense, Denmark
Background: Previous data from our centre has shown that 50-60% 
of the patients require blood transfusion when treated with palliative 
chemotherapy. EPO has not been accepted for routine use in Denmark 
due to no shortage of blood for transfusions although the patients 
may have to accept low haemoglobin (Hb) values during treatment 
before transfusion. This may lead to reduced QOL and may lead to 
early stopping of treatment, and admissions which may be avoided 
with EPO. This study was initiated to study the use of EPO to prevent 
anaemia in not yet anaemic NSCLC patients undergoing chemotherapy. 
Investigated was not just the impact of EPO on the number of blood 
transfusions, but also the number of days admitted to hospital, cycles of 
chemotherapy and QOL.
Methods: In the EPO-group treatment with epoetin beta (NeoRecor-
mon®) 30.000 IE s.c. was initiated if Hb<13 g/dL, and stopped if 
Hb>14 g/dL. 52 chemotherapy-naïve patients with advanced NSCLC 
scheduled for 6 courses of Carboplatin (AUC5, d1) and Gemcitabine 
(1000 mg/m2) in PS=0-2 accepted inclusion in the study 3/2005 to 
1/2007. A matched control group of 52 patients selected from a cohort 
of 195 patients treated 2003-2005 with CaGem without EPO. Criteria 
for matching were gender, Hb (</≥), PS (0-1/2), WBC (</≥10), stage 
(III/IV), LDH (</≥UNL), and weight loss (</≥5%). 
Results: All together the study consisted of 104 patients, 52 in the 
EPO-group, and 52 in a matched control group: 38 patients fulﬁlled 
all 7 criteria for matching, 8 patients fulﬁlled 6 criteria, and 6 patients 
fulﬁlled 5 criteria. All pairs showed match with gender, Hb, and PS. 
One pair had no match for WBC, and 3 no match for stage, 7 for LDH 
and 11 for weight loss. The groups were very similar with regard to 
major criteria not matched for (Age 63.3 vs. 62.1 years, and BMI 24.0 
vs. 24.5). 
As of March 1st, 5 patients were still receiving CaGem in the EPO-
group. 25 in the EPO-group had initial Hb<13g/dL and started with 
EPO during the ﬁrst cycle of CaGem. Of the 27 patients presenting 
with Hb≥13g/dL, 21 patients received EPO after a median time of 26 
days. 
Survival of the EPO-group and controls were 7.6 and 7.4 months. 1 
year survival was 38% and 37%. Preliminary analyses showed the 
transfusions dropped 43% from 0.95 portion blood to 0.54 per given 
cycle CaGem (p=0.16) The number of cycles of CaGem per patient 
who had fulﬁlled chemotherapy March 1st was 4.4 cycles in the EPO 
group and 4.0 in the control group (0.20). Final analyses will be per-
formed July 31st. 
Conclusions: The matched pair design worked. Preliminary analyses 
showed a trend to less transfusions, and trend to being able to receive 
more chemotherapy when EPO was applied
